Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 1014
© 2008 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bontenbal, M. Articles by Klijn, J. Search for Related Content PubMed Articles by Bontenbal, M. Articles by Klijn, J.

Abstract

Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study)

Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; MCRZ, Rotterdam, The Netherlands; Reinier de Graaf Hospital, Delft, The Netherlands; Vlietland Hospital, Schiedam, The Netherlands; Maasland Hospital, Sittard, The Netherlands; Haga Hospital, The Hague, The Netherlands

1014

Background: Treatment with trastuzumab and chemotherapy has improved the outcome of HER2-positive MBC. It is unknown what the outcome and toxicity is of monotherapy trastuzumab, followed by chemotherapy at progression, as compared to the combination of chemotherapy/trastuzumab. Methods: HER2-positive MBC pts., being eligible for first line chemotherapy were randomised between combination treatment docetaxel (TAX) (100 mg/m², q3wks)/trastuzumab (HER) (loading dose 4mg/kg, whereafter weekly 2mg/kg) (arm A) or monotherapy HER, followed upon progression by TAX (similar doses as arm A) (arm B). Further in- /exclusion criteria were adjuvant non-taxoid chemotherapy allowed, previous HER treatment not; normal ejection fraction (EF), adequate liver/renal functions and bone marrow reserve. Primary endpoint was PFS, secondary endpoints: response rate (RR), overall survival (OS) and toxicities. Kaplan-Meier curve was tested by log-rank test, RR by Pearson ²-test. Results: Of the 101 randomly selected patients, 2 were ineligible. Patient characteristics in arms A/B were not significantly (NS) different, being: median age 52/53 yrs (range 32–74); ER/PgR positive 47/47%; adjuvant chemo-/hormone therapy in 46/25% and 42/33%, respectively; prior hormone therapy for MBC in 37/36%. Objective RRs were 57% and 34% (p=0.03). PFS in arm A was 9.1 mo, while PFS on HER was 3.9 mo (p=0.0001), and after consecutive TAX 9.8 mo (arm B) (p=0.22). OS data is being analysed, and will be presented. Grade 3/4 neurosensory toxicity was only seen in arm A (6%). Other grade 3/4 toxicity was NS different (pulmonary complaints (9%), fatigue (8%), other 5%). Serious adverse events more frequently occurred in arm A (25/4), 2 toxic deaths in arm A, neutropenic fever 27/16%. LVEF decline >20% occurred in 16/15%. Conclusions: Monotherapy HER followed by monotherapy TAX yields a similar PFS as compared to combination therapy HER/TAX, and is associated with less grade 3/4 toxicity. Cardiac toxicity is NS different between both treatment modalities. Delaying cytotoxic therapy by using monotherapy HER may be a treatment option for particular patients.

No significant financial relationships to disclose.

Abstract presentation from the 2008 ASCO Annual Meeting